GleamWall
中文EN

CGEM Cullinan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.5%
ROA-50.4%
ROIC (approx.)-63.9%
Asset turnover—

Leverage & solvency

Liabilities / assets12.8%
Debt / equity0.00x
Current ratio7.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$40.17M$44.44M$42.12M$42.95M$41.97M$61.03M$41.46M$40.49M
SG&A expense$12.43M$12.82M$11.57M$12.31M$13.63M$14.77M$13.54M$14.56M
Operating income-$52.60M-$57.25M-$53.70M-$55.26M-$55.59M-$75.80M-$55.00M-$55.05M
Net income-$49.39M-$53.70M-$49.66M-$50.71M-$50.61M-$70.06M-$48.50M-$47.65M
EBITDA-$52.55M-$57.17M-$53.62M-$55.18M-$55.52M-$75.72M-$54.92M-$54.97M
EPS (diluted)————————
Balance sheet
Cash & equivalents$88.26M$78.64M$75.08M$88.33M$103.33M$72.82M$76.66M$83.00M
Short-term investments$201.31M$255.90M$276.80M$289.56M$229.26M$192.66M$227.17M$315.97M
Current assets$298.15M$341.97M$361.41M$386.76M$342.24M$275.91M$317.77M$414.67M
PP&E, net$210,000$263,000$342,000$421,000$489,000$569,000$607,000$683,000
Total assets$322.56M$363.79M$402.98M$448.37M$484.13M$520.33M$579.68M$621.82M
Current liabilities$40.13M$40.63M$35.15M$37.74M$32.76M$28.06M$27.35M$30.65M
Total liabilities$41.27M$42.03M$36.81M$39.64M$32.76M$28.18M$27.84M$31.50M
Shareholders' equity$281.28M$321.75M$366.17M$408.73M$451.37M$492.15M$551.84M$590.33M
Shares outstanding64.90M64.35M61.45M60.24M59.08M59.07M58.70M58.51M
Cash flow statement
Operating cash flow-$43.08M-$38.22M-$46.05M-$38.11M-$36.88M-$57.61M-$43.16M-$36.63M
Capital expenditure———$11,000———$0
Free cash flow———-$38.12M———-$36.63M
Investing cash flow$51.64M$40.68M$32.41M$22.39M$67.39M$53.40M$36.80M$15.96M
Financing cash flow$1.06M$1.10M$380,000$715,000$0$373,000$0$1.58M
Depreciation & amortization$53,000$79,000$79,000$79,000$79,000$77,000$76,000$77,000
Stock-based compensation$8.37M$8.45M$7.62M$7.31M$9.47M$9.89M$9.37M$9.63M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.